



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C., 20231, ON:

Date: 7/27/00

By: Franklin Dyer

Print Name: FRANKLIN DYER

DOCKET NO. 00211-US-NEW

#6 8/8/00  
Today

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of )  
 )  
 MOYER, E., et al. ) Examiner: Devi, S.  
 )  
 Serial No. 09/393,590 ) Art Unit: 1645  
 )  
 Filed: September 9, 1999 )  
 )  
 For: STABLE LIQUID FORMU- )  
 LATIONS OF BOTULINUM )  
 TOXIN )

RESPONSE TO WRITTEN RESTRICTION REQUIREMENT


Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Requirement for Restriction mailed July 10, 2000 in the above-identified application, applicants hereby elect for examination, without traverse, the claims the Examiner has designated as Group I (claims 1-28) in the above-identified application for patent.

Since the elected claims are drawn to a product, the Examiner is requested to retain the additional method claims 29-53 as pending, in accordance with the provisions of MPEP 821.04.

Respectfully submitted,



Carol A. Stratford  
Registration No. 34,444

July 27, 2000

CUSTOMER NO: **21835**  
ELAN PHARMACEUTICALS, INC.  
800 Gateway Blvd.  
South San Francisco, California 94080  
Telephone: 650/877-7432